Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NASDAQ:CMPS NASDAQ:IVA NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.26-0.9%$2.53$1.09▼$7.14$162.27M2.942.41 million shs2.03 million shsCMPSCOMPASS Pathways$6.24-0.8%$4.90$2.25▼$6.63$603.47M2.211.53 million shs1.55 million shsIVAInventiva$5.52-11.5%$5.01$1.60▼$6.55$596.93M0.6668,379 shs100,899 shsSIGASiga Technologies$8.44+2.6%$8.54$4.95▼$9.62$589.32M0.96507,619 shs517,129 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics-0.88%+1.80%-16.91%+11.88%-56.12%CMPSCOMPASS Pathways-0.79%+8.90%+21.40%+76.77%+2.30%IVAInventiva-11.54%-4.66%-0.90%+63.80%+226.63%SIGASiga Technologies+2.55%-7.76%+0.24%+22.32%+22.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.26-0.9%$2.53$1.09▼$7.14$162.27M2.942.41 million shs2.03 million shsCMPSCOMPASS Pathways$6.24-0.8%$4.90$2.25▼$6.63$603.47M2.211.53 million shs1.55 million shsIVAInventiva$5.52-11.5%$5.01$1.60▼$6.55$596.93M0.6668,379 shs100,899 shsSIGASiga Technologies$8.44+2.6%$8.54$4.95▼$9.62$589.32M0.96507,619 shs517,129 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics-0.88%+1.80%-16.91%+11.88%-56.12%CMPSCOMPASS Pathways-0.79%+8.90%+21.40%+76.77%+2.30%IVAInventiva-11.54%-4.66%-0.90%+63.80%+226.63%SIGASiga Technologies+2.55%-7.76%+0.24%+22.32%+22.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.43Hold$8.50276.11% UpsideCMPSCOMPASS Pathways 2.63Moderate Buy$16.29160.99% UpsideIVAInventiva 2.63Moderate Buy$15.57182.09% UpsideSIGASiga Technologies 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest CCCC, SIGA, IVA, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025IVAInventivaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/27/2025CCCCC4 TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IVAInventivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SIGASiga TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/23/2025CCCCC4 TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$5.00 ➝ $10.009/22/2025CCCCC4 TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $10.009/22/2025CCCCC4 TherapeuticsStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$6.009/17/2025CCCCC4 TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$8.009/16/2025CCCCC4 TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$8.009/15/2025CCCCC4 TherapeuticsStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.58M4.52N/AN/A$3.06 per share0.74CMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/AIVAInventiva$9.95M53.07N/AN/A($1.21) per share-4.56SIGASiga Technologies$138.72M4.36$0.86 per share9.84$3.02 per share2.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)CMPSCOMPASS Pathways-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/AN/ASIGASiga Technologies$59.21M$1.137.476.75N/A45.73%40.52%35.62%11/6/2025 (Estimated)Latest CCCC, SIGA, IVA, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025CCCCC4 Therapeutics-$0.43N/AN/AN/AN/AN/A10/30/2025Q3 2025CMPSCOMPASS Pathways-$0.40N/AN/AN/AN/AN/A8/7/2025Q2 2025CCCCC4 Therapeutics-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 million8/5/2025Q2 2025SIGASiga TechnologiesN/A$0.49N/A$0.49N/A$81.12 million7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A5.065.06CMPSCOMPASS Pathways0.168.828.82IVAInventivaN/A2.96N/ASIGASiga TechnologiesN/A10.098.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%CMPSCOMPASS Pathways46.19%IVAInventiva19.06%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%CMPSCOMPASS Pathways3.93%IVAInventiva32.00%SIGASiga Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15071.17 million64.96 millionOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableSIGASiga Technologies4071.61 million70.21 millionOptionableCCCC, SIGA, IVA, and CMPS HeadlinesRecent News About These CompaniesWealth Enhancement Advisory Services LLC Invests $394,000 in Siga Technologies Inc. $SIGAOctober 7 at 3:10 AM | marketbeat.comSiga Technologies (NASDAQ:SIGA) Stock Price Down 3.8% - Here's WhyOctober 6 at 7:07 PM | marketbeat.comInvestors Purchase Large Volume of Siga Technologies Call Options (NASDAQ:SIGA)October 2, 2025 | marketbeat.comGoldman Sachs Group Inc. Decreases Holdings in Siga Technologies Inc. $SIGASeptember 20, 2025 | marketbeat.comHarbor Capital Advisors Inc. Reduces Holdings in Siga Technologies Inc. $SIGASeptember 19, 2025 | marketbeat.comInvestors Buy Large Volume of Siga Technologies Call Options (NASDAQ:SIGA)September 18, 2025 | marketbeat.comHealthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse...September 11, 2025 | marketbeat.comSIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA NewsAugust 20, 2025 | seekingalpha.comSIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)August 8, 2025 | finance.yahoo.comSIGA (SIGA) Q2 Revenue Soars 272%August 7, 2025 | theglobeandmail.comSIGA Technologies (SIGA) Reports Significant Earnings DeclineAugust 6, 2025 | finance.yahoo.comSIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA fundingAugust 6, 2025 | msn.comSIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comSIGA Reports Financial Results for Three and Six Months Ended June 30, 2025August 5, 2025 | globenewswire.comSIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 ResultsJuly 29, 2025 | globenewswire.comSiga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to KnowJuly 24, 2025 | zacks.comSiga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should KnowJuly 15, 2025 | msn.comUS Market's Undiscovered Gems Featuring Three Promising Small CapsJuly 15, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Laps the Stock Market: Here's WhyJuly 9, 2025 | zacks.comSIGA Technologies Inc Dividends - MorningstarJuly 8, 2025 | morningstar.comMWhy Siga Technologies Inc. (SIGA) Outpaced the Stock Market TodayJune 26, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming SectorBy Nathan Reiff | October 7, 2025Broadcom’s VMware Push Takes Aim at Microsoft, Google, & AmazonBy Leo Miller | October 6, 2025Behind D-Wave's Massive Week (And Why Rivals Also Popped)By Nathan Reiff | October 6, 2025CCCC, SIGA, IVA, and CMPS Company DescriptionsC4 Therapeutics NASDAQ:CCCC$2.26 -0.02 (-0.88%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$2.26 +0.01 (+0.22%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.COMPASS Pathways NASDAQ:CMPS$6.24 -0.05 (-0.79%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$6.42 +0.18 (+2.88%) As of 08:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Inventiva NASDAQ:IVA$5.52 -0.72 (-11.54%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$5.59 +0.07 (+1.27%) As of 08:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Siga Technologies NASDAQ:SIGA$8.44 +0.21 (+2.55%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$8.48 +0.04 (+0.53%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
